<?xml version="1.0" encoding="UTF-8"?>
<results title="drug">
 <result pre="– ● ▲△ Interferon ● ● – – ● –" exact="Ribavirin" post="● ● – – ● – Remdesivir −e –"/>
 <result pre="– – – Favipiravir – – – – ● –" exact="Chloroquine" post="phosphate ● ● – – ● – Hydroxychloroquine sulfate"/>
 <result pre="● – Chloroquine phosphate ● ● – – ● –" exact="Hydroxychloroquine" post="sulfate – – – – – ▲△ Immunomodulator Corticosteroids"/>
 <result pre="recommended by the latest Chinese guidance7 include interferon-α, lopinavir-ritonavir, arbidol," exact="chloroquine" post="phosphate and ribavirin. And favipiravir is recommended to be"/>
 <result pre="to clinical researches, currently, the results of lopinavir-ritonavir, arbidol and" exact="Hydroxychloroquine" post="sulfate on COVID-19 treatment have been reported in 6"/>
 <result pre="treatment, lopinavir-ritonavir treatment and control group (P &amp;gt; 0.05). For" exact="hydroxychloroquine" post="sulfate: an open-label, non-randomized clinical trial18 suggested, compared with"/>
 <result pre="nucleic acid turning negative of control group (12.5%), combination of" exact="hydroxychloroquine" post="sulfate and azithromycin (100%) and monotherapy of hydroxychloroquine sulfate"/>
 <result pre="negative of control group (12.5%), combination of hydroxychloroquine sulfate and" exact="azithromycin" post="(100%) and monotherapy of hydroxychloroquine sulfate (57.1%) significantly improved"/>
 <result pre="combination of hydroxychloroquine sulfate and azithromycin (100%) and monotherapy of" exact="hydroxychloroquine" post="sulfate (57.1%) significantly improved the rate of viral nucleic"/>
 <result pre="nucleic acid turning negative (P &amp;lt; 0.001). The effect of" exact="hydroxychloroquine" post="sulfate is reinforced by azithromycin. And such combination may"/>
 <result pre="turning negative were not significant. In addition, remdesivir, favipiravir, ribavirin," exact="chloroquine" post="phosphate and other antiviral drugs are still in ongoing"/>
 <result pre="Use Authorization (EUA) for emergency use of oral formulations of" exact="chloroquine" post="phosphate and hydroxychloroquine sulfate for the treatment of COVID-19.20"/>
 <result pre="for emergency use of oral formulations of chloroquine phosphate and" exact="hydroxychloroquine" post="sulfate for the treatment of COVID-19.20 Hospital pharmacists should"/>
 <result pre="closely and dosage should be adjusted if necessary, for example," exact="ribavirin" post="may reduce the anticoagulant effect of warfarin, lopinavir-ritonavir may"/>
 <result pre="of novel coronavirus pneumoniaChin J of Infect Dis2020 18GautretP.LagierJ.-C.ParolaP.Hydroxychloroquine and" exact="azithromycin" post="as a treatment of COVID-19: results of an open-label"/>
 <result pre="non-randomized clinical trialInt J Antimicrob Agents2020 19ChenJ.LiuD.P.LiuL.A pilot study of" exact="hydroxychloroquine" post="in treatment of patients with common coronavirus disease-19 (COVID-19)Journal"/>
 <result pre="Food &amp;amp; Drug AdministrationLetter of emergency use authorization to allow" exact="hydroxychloroquine" post="sulfate and chloroquine phosphate to be distributed and used"/>
 <result pre="AdministrationLetter of emergency use authorization to allow hydroxychloroquine sulfate and" exact="chloroquine" post="phosphate to be distributed and used for certain hospitalized"/>
</results>
